Dr. Berkland serves as the Chairman of the Board, President, Chief Executive Officer (CEO), and Co-Founder of Bond Biosciences. He is taking a partial leave as Distinguished Professor at The University of Kansas to advance the business and to ensure the development and clinical trial progression of BBI-001.
Dr. Berkland has experience founding, growing, and exiting pharmaceutical companies including Orbis Biosciences (acquired by Adare Pharmaceuticals) and Savara Pharmaceuticals (NASDAQ:SVRA). Dr. Berkland served in leadership roles at each of these companies. He also has experience working in venture capital as an entrepreneur-in-residence at Sofinnova Investments in 2014.
Dr. Berkland has experience founding, growing, and exiting pharmaceutical companies including Orbis Biosciences (acquired by Adare Pharmaceuticals) and Savara Pharmaceuticals (NASDAQ:SVRA). Dr. Berkland served in leadership roles at each of these companies. He also has experience working in venture capital as an entrepreneur-in-residence at Sofinnova Investments in 2014.
Speaking In
1:45 PM - 2:00 PM
Monday, June 5
